Phase 2 N=18 Treatment

Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis

Ulcerative Colitis

Bottom Line

View on ClinicalTrials.gov: NCT00048347 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2010

Primary outcome: Primary: Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI) — 63 Percent of participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: AVONEX (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Primary completion: Jun 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI)	63	—

Summary

This study will evaluate the safety and effectiveness of the drug interferon-beta1a (AVONEX) in treating ulcerative colitis and examine the drug's effect on the immune system. People with ulcerative colitis have increased amounts of inflammatory chemicals (cytokines) made by immune cells in the lining of the colon. Studies have shown that interferon-beta may block the activity of these cytokines. Interferon-beta1a (AVONEX) is currently FDA-approved to treat multiple sclerosis, a disease involving inflammation of the brain and spinal cord. Patients 18 years of age and older who have had ulcerative colitis for at least 4 months may be eligible for this study. Candidates will be screened with a review of their medical records, a medical history and physical examination, electrocardiogram (EKG), blood, urine, and stool tests, and a pregnancy test for women of childbearing potential. A colonoscopy will also be done to determine disease activity and extent. This test uses a lighted tube to examine the amount of inflammation in the colon and take tissue samples (biopsies) for testing. Before the test, the patient is given a medicine to allay anxiety and the discomfort of inserting the endoscope into the rectum. This flexible tube allows the doctor to see the intestinal mucosa and project an image of the inner lining of the intestine onto a TV monitor. At various places in the intestine, small pieces of tissue are plucked out by a special device at the tip of the endoscope. The procedure generally lasts 30 minutes to 1 hour. Participants will come to the NIH Clinical Center once a week for 4 weeks to receive an injection of interferon-beta, fill out questionnaires, and have a symptoms check, physical examination, and blood tests. Patients whose colitis has not worsened at the end of the 4 weeks and who have not had significant drug side effects will continue to receive weekly injections for an additional 8 weeks. Some patients may receive some of the last eight injections outside of NIH, but all patients will visit the Clinical Center visits every 3 to 4 weeks for a physical exam, symptoms check and blood tests. After the 12 injections are completed, patients will have another colonoscopy to evaluate the response to treatment and will return to the Clinical Center every 6 weeks for a total of four visits, for a physical examination, symptoms check and blood tests.

Eligibility Criteria

INCLUSION CRITERIA:
Age 18 years old or greater.
Diagnosis of ulcerative colitis for at least 4 months based on endoscopic appearance or radiographic distribution of disease and corroborated with histopathology (especially the absence of granulomata).
Presence of current active disease as defined by a Simple Clinical Colitis Activity Index of greater than or equal to 5 (for either of the two measurements done during the Screening Phase and that the second measurement is within 50 percent of the value of the first) who may or may not have the presence of one of the following: current corticosteroid- dependence for disease treatment, disease refractory to corticosteroids, or history of intolerance to treatment with corticosteroids (for criterion of co-administered corticosteroid dose see below).

Corticosteroid-dependence is defined as relapse of ulcerative colitis within 60 days of completing a course of corticosteroid treatment, or during corticosteroid tapering at doses greater than or equal to 10 mg prednisone/day (or equivalent), or within three months following corticosteroid tapering while receiving a steroid dose of greater than or equal to 10 mg prednisone/day (or equivalent).

If currently receiving medication for ulcerative colitis, patients may be on a stable regimen of one or a combination of the following drug doses and durations:

Corticosteroids (less than or equal to 25 mg Prednisone/d or Prednisone equivalent) is greater than or equal to 4 weeks;

5-ASA/Sulfasalazine is greater than or equal to 4 weeks;

Azathioprine/6-MP/thioguanine is greater than or equal to 12 weeks. (Note: Patients receiving azathioprine/6-MP/thioguanine must have been on a stable dose of this medication for greater than or equal to 8 weeks before randomization);

Probiotics (live bacterial dietary supplements) greater than or equal to 4 weeks;

Prebiotics (dietary supplements to produce biologically active substances) greater than or equal to 4 weeks.

Use of barrier or hormonal methods of birth control for female subjects who are not surgically sterile or postmenopausal.
Negative serum beta-hCG for women of child-bearing potential (women who are not surgically sterile or postmenopausal) to exclude early unnoticed pregnancy.
Negative results on stool examination for culture of enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, Vibrio, E. coli O157/H7), Clostridium difficile toxin assay, enteric parasites and their ova (including Giardia and Cryptosporidia).
Thyroid function test and TSH level within establish normal range set by the Clinical Center.

EXCLUSION CRITERIA

Inability to meet any of the above inclusion criteria.
Use of any of the following medications within the specified time period prior to the first dose of interferon-beta or at any time during the study:

Non-steroidal anti-inflammatory agents (including COX-2 inhibitors), - 1 week

Corticosteroids (greater than 25 mg Prednisone/d or Prednisone equivalent), Methotrexate, Cyclosporin, Tacrolimus, Thalidomide, or Mycophenolate mofetil - 4 weeks

Monoclonal antibodies to TNF alpha or any Other Biologic (cytokine, anti-cytokine, or integrin-based therapy, for instance) - 4 months

Any experimental agent - 1 month

Concomitant use of any of the following drugs: isoniazid, iproniazid, dantrolene, ticrynafen (tienilic acid), ibufenac, bromfenac, benoxaprofen, zileutan, nicotinic acid, trovafloxacin, perhexiline, dilevavol, labetalol, pemoline, felbamate, tolcapone, diclofenac, AIDS drugs (HIV+ subjects are excluded anyway), and troglitozone.

History of colectomy, partial colectomy, current ostomy, or pouchitis.
Presence of significant electrocardiogram abnormalities including QT(c) greater than or equal to 0.48 sec, Mobitz type II second degree or third degree atrioventricular block, left bundle branch block or right bundle branch block accompanied by any fascicular block, changes consistent with acute ischemia or pericardi

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00048347). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.